Obesity, menopause, metabolic syndrome, physical capacity. Nutritional, Metabolic, Endocrine Obesity
Conditions
Interventions
All groups will be followed for 24 weeks (4 weeks of weight stabilisation before and after the intervention + 16 weeks of weight loss program). Women will be randomized to one of the four following gr
Sponsors
University of Sherbrooke (Canada)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Women will be included in the study if they had stopped menstruating for more than 1 yr, and if they have follicle stimulating hormone (FSH) levels > 30 U/L 2. Aged between 60 and 75 years old 3. Body mass index (BMI) between 27 and 40 kg/m2 4. Sedentary ( 1.70 mmol/L; high density lipoprotein (HDL)-cholesterol 6.1 mmol/L], 7) stable medication(s) for the metabolic syndrome since 6 weeks and 8. Glycated haemoglobin (HbA1c) < 8%
Exclusion criteria
Exclusion criteria: 1. More than three medications for high blood pressure 2. Cardiovascular disease and peripheral vascular disease within 3 months 3. Stroke within 3 months and/or causing inability to complete the exercice program 4. Diabetes treated with insulin 5. Cancer within 5 years (excepted skin and thyroid cancer) 6. Severe hypertension (resting blood pressure > 160/95 mmHg under stable treatement) 7. Total cholesterol > 8 mmol/L 8. Triglycerides >10 mmol/L 9. Low density lipoprotein (LDL)-chol > 4 mmol/L 9. Body weight fluctuation > 3 kg in the previous six months 10. Pituitary disease 11. Renal insufficiency (creatine 1.2 g/kg body mass per day
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Dual energy X-ray absorptiometry (DXA) technology to measure total fat mass, bone mass and lean body mass as well as each tissue by region (trunk, legs and arms). 2. Other measures of body composition include weight, height, waist and hip circumferences. They are taken before, during and after the intervention (total of 3 times for DXA outcomes and 8 times for other body composition measurements). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Lipids, glucose homeostasis, inflammation profile, adipokines, energy expenditure, resting arterial blood pressure and heart rate, physical capacity and psychosocial determinants 2. Plasma measures will be taken before, during and after the intervention (total of 3 times): Analyses will be done on the COBAS INTEGRA 400 (Roche Diagnostic, Montréal, Canada) analyzer for total cholesterol, HDL-cholesterol, triglycerides and glucose combined with specific cassettes containing in vitro diagnostic reagent system. LDL-cholesterol concentration will be calculated by Friedewald equation using total cholesterol, HDL-cholesterol and triglycerides. 2.1. Insulin and IGF-I concentrations will be determined with commercially available radioimmunoassay kits (Radioassay System Laboratory, and ICN Biomedicals, Costa Mesa, CA; distributed by Immunocorp, Montreal, PQ, and Diagnostic Systems aboratories-2900, respectively). 2.2. Plasma IGFBP-1,2,3 will be determined by Western blotting. 2.3. Serum adiponectin and leptin (Linco Research, St-Charles, MO, USA) levels will be measured in duplicate with a commercial radioimmunoassay (RIA) procedure using 125I-labeled bioactive human adiponectin and leptin as tracers and a rabbit polyclonal antibody raised against full-length peptides. 2.4. Plasma immunoreactive total and acylated ghrelin levels will be measured in duplicate with a commercial RIA using 125I-labeled bioactive human acylated ghrelin as tracers and rabbit polyclonal antibody raised against full-length total ghrelin and against the Ser3-octanoylated portion of acylated ghrelin, respectively (Linco Research, St. Charles, MO). 2.5. Nonacylated ghrelin values will be calculated as total minus acylated ghrelin. NPY will be measured by RIA kits (Peninsula Lab., Belniont, CA) after plasma extraction on reverse-phase minicolunins. CRP will be measured using an enzyme-linked immunosorbent assay based on purified protein and polyclonal anti-CRP antibodies (sensitivity: 0.08 µg/ml | — |
Countries
Canada
Outcome results
None listed